Kang-Hao Liang

1.3k total citations · 1 hit paper
20 papers, 724 citations indexed

About

Kang-Hao Liang is a scholar working on Infectious Diseases, Oncology and Molecular Biology. According to data from OpenAlex, Kang-Hao Liang has authored 20 papers receiving a total of 724 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Infectious Diseases, 7 papers in Oncology and 6 papers in Molecular Biology. Recurrent topics in Kang-Hao Liang's work include SARS-CoV-2 and COVID-19 Research (10 papers), Cancer Cells and Metastasis (6 papers) and Viral gastroenteritis research and epidemiology (5 papers). Kang-Hao Liang is often cited by papers focused on SARS-CoV-2 and COVID-19 Research (10 papers), Cancer Cells and Metastasis (6 papers) and Viral gastroenteritis research and epidemiology (5 papers). Kang-Hao Liang collaborates with scholars based in Taiwan. Kang-Hao Liang's co-authors include Han‐Chung Wu, Feng-Yi Ke, Ruei‐Min Lu, Shih-Chieh Su, Shih-Han Ko, Yi‐Ping Wang, Hsiu-Ting Lin, Chen Wy, Yi‐Ting Chuang and Meng‐Ru Ho and has published in prestigious journals such as Cancer Research, Scientific Reports and Nature Structural & Molecular Biology.

In The Last Decade

Kang-Hao Liang

19 papers receiving 714 citations

Hit Papers

Monoclonal antibodies for COVID-19 therapy and SARS-CoV-2... 2022 2026 2023 2024 2022 50 100 150
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Monoclonal antibodies for COVID-19 therapy and SARS-CoV-2 detection
    2022 157 citations Ruei‐Min Lu, Shih-Chieh Su et al. Journal of Biomedical Science profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Kang-Hao Liang Taiwan 11 323 320 170 90 84 20 724
Kosi Gramatikoff United States 9 297 0.9× 385 1.2× 96 0.6× 53 0.6× 69 0.8× 12 798
Emanuele Marra Italy 18 215 0.7× 365 1.1× 242 1.4× 106 1.2× 51 0.6× 36 761
Feng-Yi Ke Taiwan 5 190 0.6× 190 0.6× 75 0.4× 49 0.5× 58 0.7× 7 426
Joseph S. Bednash United States 15 262 0.8× 396 1.2× 121 0.7× 173 1.9× 83 1.0× 34 770
Richard Ingram United States 12 182 0.6× 187 0.6× 100 0.6× 107 1.2× 26 0.3× 14 566
Zufan Debebe United States 12 116 0.4× 327 1.0× 80 0.5× 191 2.1× 64 0.8× 17 823
Alessia Liguori Italy 10 104 0.3× 293 0.9× 146 0.9× 179 2.0× 113 1.3× 19 631
Byoung Kwon Park South Korea 15 165 0.5× 190 0.6× 65 0.4× 129 1.4× 21 0.3× 30 434
Lori A. Emert‐Sedlak United States 16 272 0.8× 297 0.9× 57 0.3× 198 2.2× 36 0.4× 23 808
Bhavisha Rathod Canada 8 150 0.5× 555 1.7× 52 0.3× 57 0.6× 52 0.6× 16 793

Countries citing papers authored by Kang-Hao Liang

Since Specialization
Citations

This map shows the geographic impact of Kang-Hao Liang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kang-Hao Liang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kang-Hao Liang more than expected).

Fields of papers citing papers by Kang-Hao Liang

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kang-Hao Liang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kang-Hao Liang. The network helps show where Kang-Hao Liang may publish in the future.

Co-authorship network of co-authors of Kang-Hao Liang

This figure shows the co-authorship network connecting the top 25 collaborators of Kang-Hao Liang. A scholar is included among the top collaborators of Kang-Hao Liang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kang-Hao Liang. Kang-Hao Liang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Lu, Ruei‐Min, Hsiao-Ling Chiang, Kang-Hao Liang, et al.. (2025). Technological advancements in antibody-based therapeutics for treatment of diseases. Journal of Biomedical Science. 32(1). 98–98.
2.
Kumari, Monika, Kang-Hao Liang, Shih-Chieh Su, et al.. (2024). Multivalent mRNA Vaccine Elicits Broad Protection against SARS-CoV-2 Variants of Concern. Vaccines. 12(7). 714–714. 3 indexed citations
3.
Kumari, Monika, Shih-Chieh Su, Kang-Hao Liang, et al.. (2023). Bivalent mRNA vaccine effectiveness against SARS-CoV-2 variants of concern. Journal of Biomedical Science. 30(1). 46–46. 5 indexed citations
4.
Lee, Chi‐Chiu, et al.. (2023). Epithelial cell adhesion molecule (EpCAM) regulates HGFR signaling to promote colon cancer progression and metastasis. Journal of Translational Medicine. 21(1). 530–530. 11 indexed citations
5.
Lu, Ruei‐Min, Kang-Hao Liang, Hsiao-Ling Chiang, et al.. (2023). Broadly neutralizing antibodies against Omicron variants of SARS-CoV-2 derived from mRNA-lipid nanoparticle-immunized mice. Heliyon. 9(5). e15587–e15587. 4 indexed citations
6.
Chiang, Hsiao-Ling, et al.. (2023). Broadly neutralizing human antibodies against Omicron subvariants of SARS-CoV-2. Journal of Biomedical Science. 30(1). 59–59. 7 indexed citations
7.
Ko, Shih-Han, Chen Wy, Shih-Chieh Su, et al.. (2022). Monoclonal antibodies against S2 subunit of spike protein exhibit broad reactivity toward SARS-CoV-2 variants. Journal of Biomedical Science. 29(1). 108–108. 7 indexed citations
8.
Hsu, Fu‐Fei, Kang-Hao Liang, Monika Kumari, et al.. (2022). An efficient approach for SARS-CoV-2 monoclonal antibody production via modified mRNA-LNP immunization. International Journal of Pharmaceutics. 627. 122256–122256. 18 indexed citations
9.
Lu, Ruei‐Min, Shih-Chieh Su, Shih-Han Ko, et al.. (2022). Monoclonal antibodies for COVID-19 therapy and SARS-CoV-2 detection. Journal of Biomedical Science. 29(1). 1–1. 157 indexed citations breakdown →
10.
Kumari, Monika, Ruei‐Min Lu, Mu‐Chun Li, et al.. (2022). A critical overview of current progress for COVID-19: development of vaccines, antiviral drugs, and therapeutic antibodies. Journal of Biomedical Science. 29(1). 68–68. 94 indexed citations
11.
Li, Hsin‐Jung, Feng-Yi Ke, Chia-Ching Lin, et al.. (2021). ENO1 Promotes Lung Cancer Metastasis via HGFR and WNT Signaling–Driven Epithelial-to-Mesenchymal Transition. Cancer Research. 81(15). 4094–4109. 101 indexed citations
12.
Liang, Kang-Hao, Shih-Han Ko, Yu‐Chi Chou, et al.. (2021). Antibody cocktail effective against variants of SARS-CoV-2. Journal of Biomedical Science. 28(1). 80–80. 17 indexed citations
13.
Yang, Tzu‐Jing, Pei‐Yu Yu, Yuan‐Chih Chang, et al.. (2021). Effect of SARS-CoV-2 B.1.1.7 mutations on spike protein structure and function. Nature Structural & Molecular Biology. 28(9). 731–739. 103 indexed citations
14.
Liang, Kang-Hao, et al.. (2020). EpCAM Signaling Promotes Tumor Progression and Protein Stability of PD-L1 through the EGFR Pathway. Cancer Research. 80(22). 5035–5050. 54 indexed citations
15.
Liang, Kang-Hao, et al.. (2019). Abstract 4670: The molecular mechanisms of EpCAM in regulating tumor progression in colon cancer cells. Cancer Research. 79(13_Supplement). 4670–4670. 1 indexed citations
16.
17.
Liang, Kang-Hao, Feng-Yi Ke, Yi‐Ting Chuang, et al.. (2018). Extracellular domain of EpCAM enhances tumor progression through EGFR signaling in colon cancer cells. Cancer Letters. 433. 165–175. 61 indexed citations
18.
Liang, Kang-Hao, Yi‐Ping Wang, Yaa‐Jyuhn James Meir, et al.. (2017). EpEX/EpCAM and Oct4 or Klf4 alone are sufficient to generate induced pluripotent stem cells through STAT3 and HIF2α. Scientific Reports. 7(1). 41852–41852. 39 indexed citations
19.
Liang, Kang-Hao, et al.. (2017). Abstract 327: EpCAM/EpEX regulate tumor progression through EGFR signaling in colon cancer cells. Cancer Research. 77(13_Supplement). 327–327. 2 indexed citations
20.
Kuo, Mark Yen‐Ping, et al.. (2015). An anti-EpCAM antibody EpAb2-6 for the treatment of colon cancer. Oncotarget. 6(28). 24947–24968. 39 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Kosi Gramatikoff Breakdown of academic impact, for papers by Emanuele Marra Breakdown of academic impact, for papers by Feng-Yi Ke Breakdown of academic impact, for papers by Joseph S. Bednash Breakdown of academic impact, for papers by Richard Ingram Breakdown of academic impact, for papers by Zufan Debebe Breakdown of academic impact, for papers by Alessia Liguori Breakdown of academic impact, for papers by Byoung Kwon Park Breakdown of academic impact, for papers by Lori A. Emert‐Sedlak Breakdown of academic impact, for papers by Bhavisha Rathod
Rankless by CCL
2026